Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

support provided by the HVTN."

Dr. McNally concluded, "We believe we are well-positioned for success in 2009 and beyond, with our preventative vaccine beginning Phase 2 human testing and our therapeutic vaccine trial in the planning stage. Based on highly promising results in preclinical non-human primate studies conducted by Dr. Rama Amara at Emory University, we are eager to launch a therapeutic Phase 1/2 human clinical trial in individuals already infected with HIV to investigate the use of our vaccine as a therapeutic treatment to control HIV-virus levels. We expect this trial may start in mid-2009 and we will report on the development of this program as we conclude plans with our trial sponsor."

GEOVAX LABS, INC.

Condensed Consolidated Statements of Operations Information

(amounts in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Grant Revenue $1,322 $- $2,298 $-

Operating expenses:

Research and

development 1,362 360 2,725 1,273

General and

administrative 699 815 2,322 1,865

2,061 1,175 5,047 3,138

Other income:

Interest income 17 9 60 52

17 9 60 52

Net loss $(722) $(1,166) $(2,689) $(3,086)

Loss per common share $(0.00) $(0.00) $(0.00) $(0.00)

GEOVAX LABS, INC.

Con
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Custom Computer Specialists, Inc. ("Custom"), a leading healthcare IT ... of the Primary Care Development Corporation,s ("PCDC") Corporate Circle. ... support of PCDC,s mission to expand access to primary ... in 1993, PCDC has been a key force of ... over 100 completed primary care projects, valued at over ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
(Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
(Date:6/29/2015)... MO (PRWEB) , ... June 29, 2015 , ... The ... – July 16 and for the fourth year in a row, will bring top ... changes are taking place at the intersection of data and technology. The event is ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3
... , , , , ... MON ) R&D pipeline is on the verge of ... improved yield for growers and has the company poised to meet ... executive officer and president, will tell investors today. , , ...
... August 13 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader in the field ... of 2009. , , Highlights, - ... in Canada following two previous clinical trials, - ... a clinically important health benefit, accomplished by a significant, ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... its financial results for the second quarter ended June 30, ... pleased to report in April that the FDA accepted Auxilium,s ... Dupuytren,s disease and we are looking forward to the Arthritis ...
Cached Biology Technology:Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7Amsterdam Molecular Therapeutics Reports Half Year Results 2009 2Amsterdam Molecular Therapeutics Reports Half Year Results 2009 3Amsterdam Molecular Therapeutics Reports Half Year Results 2009 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... -- This report analyzes the worldwide markets for Immunoassay ... which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay Systems, ... and Nephelometric Immunoassay Systems. The report provides separate comprehensive ... Japan , Europe ... America , and Rest of World. Annual estimates ...
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... as the 2007 winner of the ALPSP/Charlesworth Award for ... a significantly innovative approach to any aspect of scholarly ... years award was RSC Project Prospect from the Royal ... semantics into chemical science publishing. RSC Project Prospect journals ...
... of HIV research through his rational approach to trying to ... method is based on gaining an understanding of the molecular ... sites on the virus that the antibodies target a ... molecules used in an HIV-1 vaccine. He has published ...
... Washington, DC September 13, 2007 One of the 2007 ... sponsored by ASM will be presented to Hung Ton-That, ... and Structural Biology, University of Connecticut Health Center. ... in microbiology and infectious disease. Dr. Ton-Thats ...
Cached Biology News:RSC Project Prospect scoops prestigious award 2
...
Request Info...
... Cultrex High Protein Concentration Basement Membrane ... use in in vivo applications where ... times, increased gel strength, and elevated ... has the advantage of lot-to-lot consistency ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
Biology Products: